PDS Biotechnology Corp Income (Loss) from Continuing Operations, Per Basic Share
PDS Biotechnology Corp (PDSB) reported Income (Loss) from Continuing Operations, Per Basic Share of -$0.19 per share for the 3-month period ending 2020-06-30, per its 10-Q filed 2020-08-13.
Discontinued › Expense Statement › Operating Expenses
us-gaap:IncomeLossFromContinuingOperationsPerBasicShare · last filed 2020-08-13
- PDS Biotechnology Corp income (loss) from continuing operations, per basic share for the quarter ending 2020-06-30 was -$0.19.
- PDS Biotechnology Corp income (loss) from continuing operations, per basic share for the quarter ending 2020-03-31 was -$0.39, a 121.43% decline year-over-year.
- PDS Biotechnology Corp income (loss) from continuing operations, per basic share for the quarter ending 2019-06-30 was -$0.75.
- PDS Biotechnology Corp income (loss) from continuing operations, per basic share for the quarter ending 2019-03-31 was $1.82.
| Period end | Income (Loss) from Continuing Operations, Per Basic Share 3 month | Income (Loss) from Continuing Operations, Per Basic Share 6 month |
|---|---|---|
| 2020-06-30 | -$0.19 10-Q · filed 2020-08-13 | -$0.54 10-Q · filed 2020-08-13 |
| 2020-03-31 | -$0.39 10-Q · filed 2020-05-13 | |
| 2019-06-30 | -$0.75 10-Q · filed 2020-08-13 | $0.66 10-Q · filed 2020-08-13 |
| 2019-03-31 | $1.82 10-Q · filed 2020-05-13 | |
| 2018-06-30 | -$0.17 10-Q · filed 2019-08-01 | -$0.41 10-Q · filed 2019-08-01 |
| 2018-03-31 | -$0.24 10-Q · filed 2019-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |